Sorin Group S.p.A. Release: ANSWER Study Shows That Safer™ Safely Reduces Right Ventricular Pacing In Pacemaker Patients And Subsequently Improves Clinical Outcomes

NICE, France--(BUSINESS WIRE)--Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced the results of the ANSWER clinical study. The trial results were presented at CARDIOSTIM 2014 Annual Scientific Sessions, in Nice, France, by Dr. Martin Stockburger, Charité University Hospital Berlin, Germany.

Help employers find you! Check out all the jobs and post your resume.